Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

COMPACT

Financiado

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Ce...

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, m... ver más

31/10/2017

SANOFIAVENTIS DEUT...

30M€

Presupuesto del proyecto: 30M€

Líder del proyecto

SANOFIAVENTIS DEUTSCHLAND GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 20 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2017-10-31

0% 100%

20 Participantes

SANOFIAVENTIS DEUTSCHLAND GM...

Lider

Pfizer RD UK Limited

N.D. | Participante

ABBV

N.D. | Participante

LMU MUENCHEN

N.D. | Participante

Proyectos interesantes

RatInhalRNA Rational and Simulation-Supported Design of Inhalable RNA Na... 2M€ Cerrado

RNhale Dry Powder Formulation of RNA Nanoparticles for Inhalation a... 150K€ Cerrado

PID2019-107500RB-I00 BIOMORPHIC PLATFORMS FOR THE PULMONARY DELIVERY OF NANOTHERA... 97K€ Cerrado

RTC-2016-5260-1 Ensayo fase I para determinar el perfil farmacocinético y la... 605K€ Cerrado

PNANOMED Personalized Nanomedicines for Leukemia Patients 1M€ Cerrado

MAT2010-20370 CARACTERIZACION FISICO-QUIMICA DE SISTEMAS COLOIDALES DE INT... 133K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 59 meses Fecha Inicio: 2012-11-01
Fecha Fin: 2017-10-31

Líder del proyecto

SANOFIAVENTIS DEUTSCHLAND GMBH

TRL 4-5

Presupuesto del proyecto 30M€

Descripción del proyecto Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into therapeutic products. Solving the bottleneck of BP delivery is one of the main incentives of the pharmaceutical industry as this would allow a broadening of the spectrum of potential targets for therapeutic intervention needed to fill their drug pipelines. COMPACT represents Europe’s frontrunners in pharmaceutics, nanotechnology, biology, chemistry, engineering and imaging who will work in close collaboration with EFPIA on the delivery issues with BP. The main objectives are (1) to identify and understand transport pathways across biological barriers and cell membranes that can be utilized for delivery of BP, (2) to construct, characterise and preclincally validate BP formulations for non-invasive delivery of BP, with an emphasis on oral, airway and (trans)dermal delivery and for transport over the BBB. This will be achieved by setting up sophisticated in vitro models of biological barriers and appropriate animal models to find pathways that can be used for effective delivery of BP. In parallel, we will alter the BP either by chemical or biological engineering or by nano-formulations to enhance their uptake or transport over biological barriers.To be able to follow the transport,advanced imaging techniques will be utilised. The unique feature of this consortium is the alliance of experts in different research fields that complement each other in this challenging task. It is only the concerted action of such an interdisciplinary consortium that can make a difference in finding constructive solutions to the problem of poor bioavailability and target accessibility of BP.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores